Biosimilar competition saves US healthcare $21 billion
European Pharmaceutical Review
OCTOBER 14, 2022
Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. More interchangeable biosimilars are estimated to be approved and launched in the US in the next few years.
Let's personalize your content